Healthspan Economy

ClinicalTrials.gov · NCT04608448 · Completed

Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock

Registry record

NCT04608448 on ClinicalTrials.gov. The registry's last update to this record was 19 July 2023.

Date checked: . This is the day the Atlas read the registry record; the registry may have changed since.

Verification record

5 checked · 0 company says · 0 reported · 0 not found · 0 not yet checked

  • Title as registered Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock Checked Source clinicaltrials.gov Brief title as registered. Checked
  • Sponsor The University of Texas Health Science Center at San Antonio Checked Source clinicaltrials.gov Lead sponsor as registered. Checked
  • Intervention Rapamycin Topical Ointment; Placebo Checked Source clinicaltrials.gov Intervention names as registered. Checked
  • Primary outcome as registered Change in Epigenetic Markers Checked Source clinicaltrials.gov Primary outcome measure(s) as registered. Checked
  • Status Completed Checked Source clinicaltrials.gov Overall status as registered; registry last update 2023-07-19. Checked

Check history: NCT04608448 was last read on the registry on November 14, 2026. No earlier checks are recorded. How records are checked.

Corrections: none recorded for this trial. To ask for one, write to [email protected] with the registry number; every correction is checked against the registry record before the record changes.

As registered

  • Sponsor: The University of Texas Health Science Center at San Antonio
  • Phase: Early Phase 1
  • Status: Completed
  • Intervention: Rapamycin Topical Ointment; Placebo
  • Primary outcome: Change in Epigenetic Markers
  • Countries: United States
  • Start: 28 April 2021
  • Completion (actual): 15 April 2022

Results

Results are posted on the registry. Read them on ClinicalTrials.gov. The Atlas does not summarize findings.

Related modality

A trial being registered is not evidence that the intervention works.